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ABSTRACT 
Objective: Tolterodine tartrate (tolterodine) is used for treating overactive bladder (OAB) with symptoms of urinary frequency, urgency and 
leakage. Tolterodine is an antimuscarinic (anticholinergic) agent. It works by blocking a chemical that causes contractions of the bladder. Present 
work involved development of a novel drug delivery system of tolterodine intended to be taken once daily. 
Methods: Extended release (ER) pellets of tolterodine were prepared and optimized for in vitro drug release. Subsequently, these pellets were filled 
into a suitable sized capsule. The resulting capsules were evaluated for in vitro drug release. Optimized formulation was subjected to accelerated 
stability studies for 3 mo and was evaluated for description, average weight, assay and drug release. 
Results: The optimized ER capsule exhibited similar dissolution profile as that of the reference listed drug (RLD), with approximately 45%, 75% and 
more than 80% release in 3 h, 5 h and 7 h respectively. Accelerated stability studies indicated good physical and chemical stability of the formulation. 
Conclusion: ER formulation of tolterodine was optimized and can be used as once a day dosage, reducing the frequency of administration when 
compared with the immediate release formulation. The developed formulation exhibited similar behavior as that of reference formulation Detrol LA 
marketed in the US. 
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Tolterodine, antimuscarinic (anticholinergic) agent is indicated for 
treating OAB with symptoms of urinary frequency, urgency and 
leakage [1, 2]. Tolterodine acts as a competitive antagonist 
of acetylcholine at postganglionic muscarinic receptors. Both 
urinary bladder contraction and salivation are mediated via 
cholinergic muscarinic receptors. After oral administration, 
tolterodine is metabolized in the liver, resulting in the formation of 
5-hydroxymethyl tolterodine (5-HMT), the major pharmacologically 
active metabolite. 5-HMT, which exhibits an antimuscarinic activity 
similar to that of tolterodine, contributes significantly to the 
therapeutic effect. Both tolterodine and 5-HMT exhibit a high 
specificity for muscarinic receptors, since both show negligible 
activity and affinity for other neurotransmitter receptors and other 
potential cellular targets, such as calcium channels [3]. 
The international continence society (ICS) defines incontinence as 
the involuntary loss of bladder or bowel control.  
Urinary incontinence (UI) is a stigmatized, under-reported, under-
diagnosed, under-treated condition that is erroneously thought to be 
a normal part of aging. One-third of men and women aged 30-70 
believe that incontinence is part of aging to accept. 
Information on healthy bladder function can help promote the 
understanding that incontinence is not a normal part of aging but a 
symptom of another problem. 
The social costs of UI are high and even mild symptoms affect social, 
sexual, interpersonal, and professional function. 
For urge incontinence, medications known as anticholinergics/ 
antimuscarinics (tolterodine, oxybutynin chloride, darifenacin, 
fluoxetine hydrochloride, and solifenacin succinate) can 
prevent bladder spasms and OAB.  
At the time of research, there was no alternative formulation 
available other than innovator which was patented and costly. The 
aim of the present study was to develop a formulation using simpler 
techniques and circumventing the technology used by the innovator 
product in order to have technological and commercial advantage 
along with benefit to society. 
In the present research work tolterodine was selected for the 
development of an ER [4] formulation which was developed as a 
generic version of Detrol LA, marketed by Pfizer-Pharmacia and 
Upjohn Co. 
The study was directed towards the development of a novel drug 
delivery system based on pelletization technique and was limited to 
the development of a formulation which can be commercially 
exploited for well-being of society in general and meant for the US 
market in particular. 
MATERIALS AND METHODS 
Chemicals and reagents 
Tolterodine was procured from Cipla, Mumbai, India; surelease E-7-
19010, sugar spheres and hypromellose 2910 USP were procured 
from Colorcon India Ltd, microcrystalline cellulose and mannitol 
were procured from Signet chemical, Mumbai, India; dibutyl 
sebacate was received as a gift sample from Vertellus specialties Inc., 
USA; hypromellose phthalate HP 55 was received as a gift sample 
from Shin-Etsu., Japan; isopropyl alcohol and methylene chloride 
was procured from Avantor, India; talc was received as a gift sample 
from Connell bros., Mumbai, India and empty hard gelatin capsule 
(EHGC) shells were received as gift samples from Associated 
capsules Ltd., Mumbai, India.  
Equipments 
rapid mixer granulator (RMG) (Gansons-3l), Gansons Ltd, Mumbai, 
India; extruder-sperodizer (USPH-60), Umang Pharmatech, India; 
fluid bed equipment (GPCG 1.1), Pam Glatt, India; blender (3l), RP 
products, India. 
Methods 
Preparation of immediate release core pellets of tolterodine 
Trials to formulate the core immediate release pellets of tolterodine 
(table 1). 
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Table 1: Composition of immediate release pellets of tolterodine 
Ingredients Function 4/F051A 4/F052 4/F079B 4/F113B 4/F117D 4/F127A 4/F187 
mg/capsule 
Drug core by extrusion spheronisation 
Tolterodine tartrate Active 4 4 NA NA NA 4 4 
Microcrystalline cellulose (Avicel PH 101) Diluent 128 128 NA NA NA 128 100 
Mannitol Diluent NA NA NA NA NA NA 28 
Hypromellose, 2910 (Methocel E5) Binder 10 10 NA NA NA 10 10 
Purified water  Solvent qs qs NA NA NA qs qs 
Average weight (mg)  142 142 NA NA NA 142 142 
Drug core by drug loading in fluid bed equipment 
Tolterodine tartrate Active NA NA 3.6 3.6 3.6 NA NA 
Sugar spheres USNF (20-25#) Inert core NA NA 137.25 137.25 137.25 NA NA 
Hypromellose, 2910 (Methocel E5) Binder NA NA 0.68 0.68 0.68 NA NA 
Purified water  Solvent NA NA qs qs qs NA NA 
Average weight (mg)  NA NA 141.53 141.53 141.53 NA NA 
mg: milligram, NA: not applicable, qs: quantity sufficient 
 
A total of 7 formulations were prepared. Extrusion and 
spheronisation was followed for batches 4/F051A, 4/F052, 4/F127A 
and 4/F187 where Tolterodine, microcrystalline cellulose and 
mannitol (present only in 4/F187) were sifted through 30 mesh 
sieve. The resultant material was mixed in a RMG for 10 min. 
Methocel E5 was dissolved in water and the dry mix was granulated 
with this binder solution which was followed by extrusion, 
spheronozation and drying. 
Pellets of batch numbers 4/F079B, 4/F113B and 4/F117D prepared 
using fluid bed coating process where Tolterodine and methocel E5 
were dissolved in water. This drug solution was sprayed onto sugar 
spheres in fluid bed equipment and then pellets were dried. 
Evaluation of pellets 
The pellets of all the seven batches were evaluated for loss on drying 
using Mettler Toledo IR moisture analyzer. 
 
ER coating of the core pellets 
Table 2: Formulae for the ER coating of tolterodine immediate release pellets 
Ingredients Function 4/F051A 4/F052 4/F079B 4/F113B 4/F117D 4/F127A 4/F187 
mg/capsule 
ER coating 
Tolterodine tartrate drug coated 
pellets 
Drug coated pellets 142 142 141.53 141.53 141.53 142 142 
Surelease E-7-19010 Rate controlling polymer 21.25 21.25 28.8 19.8 18 21.875 35 
Hypromellose, 2910 (Methocel E5) Channeling agent 3.75 3.75 3.2 2.2 2 3.123 NA 
Purified water  Solvent qs qs qs qs qs qs qs 
Average weight (mg)  167 167 173.53 163.53 161.53 167 177 
mg: milligram, ER: Extended release, qs: quantity sufficient  
 
Methocel was dissolved in water which was later added into 
surelease dispersion, this resultant dispersion was sprayed onto 
immediate release drug pellets into fluid bed equipment followed by 
drying.
  
Delayed release (DR) and immediate release (IR) coating of the ER pellets 
Table 3: Formulae for the DR coating of tolterodine ER pellets 
Ingredients function 4/F051A 4/F052 4/F079B 4/F113B 4/F117D 4/F127A 4/F187 
mg/capsule 
DR coating 
Tolterodine ER coated pellets ER coated pellets NA 167 NA NA NA 167 NA 
Hypromellose phthalate HP55 Enteric polymer NA 6 NA NA NA 6 NA 
Dibutylsebacate, NF Plasticizer NA 0.8 NA NA NA 0.8 NA 
Hypromellose, 2910 USP (Methocel E5) Channeling agent NA 2 NA NA NA 2 NA 
Talc, USP Anti-tacking agent NA 1.2 NA NA NA 1.2 NA 
Isopropyl alcohol, USP Solvent NA qs NA NA NA qs NA 
Methylene chloride, NF Solvent NA qs NA NA NA qs NA 
Average weight (mg)  - 177 - - - 177 - 
IR coating 
Tolterodine ER coated pellets ER coated pellets NA NA 173.53 163.53 161.53 NA NA 
Tolterodine tartrate Active NA NA 0.4 0.4 0.4 NA NA 
Hypromellose, 2910 (Methocel E5) Binder  NA NA 0.07 0.07 0.07 NA NA 
Purified water  Solvent  NA NA qs qs qs NA NA 
Average weight (mg)  - - 174 164 162 - - 
Blending 
Purified talc NF Glidant 2 2 2 2 2 2 2 
Average weight (mg)  169 179 176 166 164 179 179 
Capsule filling 
EHGC 1 No.  43 43 43 43 43 43 43 
Total weight of capsule (mg)  212 222 219 209 207 222 222 
DR: delayed release, NA: not applicable, qs: quantity sufficient, mg: milligram, IR: immediate release 
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Hypromellose phthalate and Methocel E5 were dissolved in a 
mixture of isopropyl alcohol and methylene chloride. Dibutyl 
sebacate was added to this solution followed by dispersion of talc. 
This dispersion was sprayed on Tolterodine ER pellets of batch 
number 4/F052 and 4/F127A in fluidized bed equipment and then 
dried. Dried pellets were blended with talc and filled into capsules 
shells 
Reproducibility trial and accelerated stability studies 
Batch 4/F191 was prepared similar to the composition of the batch 
4/F187 in order to evaluate reproducibility and the stability profile 
of the formulation. The capsules were packed in 30cc HDPE bottles 
and subjected to accelerated storage conditions of 40 °C/75 % 
relative humidity. Samples were evaluated at the time intervals of 1, 
2 and 3 mo. 
Statistical analysis 
One way analysis of variance (ANOVA) was employed to assess the 
difference between the assay values of initial and that of stability 
samples using Sigma Stat software (Sigma stat 2.03, SPSS). The 
observed p values of>0.05 were considered statistically significant 
for the test. Similar statistical test was applied to find difference in 
the in vitro drug release at each time point among stability samples. 
RESULTS AND DISCUSSION 
The aim of the present study was to develop an ER formulation of 
tolterodine which can be used as once a day therapy and was 
developed as a generic version of Detrol LA marketed by Pfizer-
Pharmacia and Upjohn Co. by employing pelletization technique and 
layer building method. 
Several trials were conducted (as shown in table 1, 2 and 3) using 
different % of ER coating, employing DR coating on to the ER coating 
and changing the ratio of ER polymer to channel former. 
As seen from the data, drug release from all the trials having batch 
numbers 4/F051A, 4/F052, 4/F079B, 4/F113B, 4/F117D and 
4/F127A with ER polymer ranging between 18 mg to 21.875 mg 
were slow in release compared to Detrol LA. Further, the batches 
4/F052 and 4/F127A with DR coating over ER coating have not 
shown much improvement with respect to drug release. The batches 
4/F079B, 4/F113B, 4/F117D with IR coating on ER coating have not 
shown much improvement with respect to drug release. Surprisingly 
batch number 4/F187 with highest ER polymer of 35 mg showed 
more drug release compared to other batches and was similar to the 
drug release profile of Detrol LA. 
The ER coating of batch 4/F187 was formulated without a channel 
former. Surprisingly it showed improvement in release. This was 
attributed to the presence of mannitol in core pellets of the batch 
4/F187, which has helped in dissolution of drug in the core and this 
solution in the core has created an osmotic effect. Since there was no 
channel former in the outer ER layer, the ethyl cellulose present in 
the outer layer was forced to swell and the osmotic pressure from 
core pellets expelled the drug in a controlled fashion through the 
swollen ethyl cellulose layer. There are references which mentions 
that osmotic pressure created by using osmotic agent/osmogent [5, 
6] causes pellets to burst and dump the drug [7], however the 
tolterodine formulation developed as pellets in this study does not 
cause the burst and does not dump the drug, this is evident by 
similar dissolution of the formulation 4/F187 (with an osmotic 
agent) compared against reference product Detrol LA where osmotic 
agent is not part of formulation. 
 
Table 4: Evaluation of capsule formulations of tolterodine 
Evaluation parameter C100378 
Detrol LA 
4/F051A 4/F052 4/F079B 4/F113B 4/F117D 4/F127A 4/F187 
Average weight (mg) 229±2.2 212±2.7 222±1.7 218.53±2.1 208.53±2.5 206.53±1.9 222±0.9 222±1.8 
Lock length (mm) 15.9±0.3 15.9±0.3 15.9±0.3 15.9±0.3 15.9±0.3 15.9±0.3 15.9±0.3 15.9±0.3 














Drug release at 1 h (%) 8±2.1 8±2.2 7±0.9 10±0.9 12±0.9 13±4.5 7±2.2 8±1.8 
Drug release at 3 h (%) 45±0.8 40±1.8 40±1.8 20±01.2 24±0.9 29±2.2 40±1.8 43±0.9 
Drug release at 5 h (%) 73±2.3 58±0.9 64±0.9 33±2.2 38±2.8 44±3.1 66±0.9 74±2.7 
Drug release at 7 h (%) 81±1.2 66±4.5 75±3.6 44±2.1 50±1.9 56±1.8 77±1.2 83±1.8 
Drug release at 9 h (%) 85±1.9 70±1.8 82±4.5 52±0.9 60±2.2 65±1.2 83±0.9 85±3.1 
Drug release at 12 h (%) 86±0.9 78±3.9 89±0.9 62±2.2 69±0.9 74±0.9 91±1.8 86±1.4 
mm: millimeter, h: h, mg: milligram, Values of assay and drug release are represented as mean±standard deviation, n=3, n=6 respectively 
 
 
Fig. 1: In vitro drug release of tolterodine tartrate from Extended Release pellets prepared with different palletization techniques and 
different composition, (Values of in vitro drug release are represented as mean, n=6). 
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Accelerated stability studies 
Batch 4/F191 a reproducibility batch of 4/F187 behaved similar as 
that of batch 4/F187. Since batch 4/F187 was having similar 
dissolution profile as that of RLD (C100378) and batch 4/F191 was 
reproducibility batch of 4/F187, it was chosen for stability studies. 
Stability samples of batch 4/F191 when evaluated at various time 
intervals, showed no significant difference in appearance or other 
physical traits as compared to initial samples (table 6). Statistical 
analysis of assay values of stability samples indicated no significant 
difference. In vitro release profiles of samples when compared with 
that of initial using ANOVA exhibited no significant difference thus 
indicating overall good stability of the formulation at accelerated 
conditions.
 
Table 6: Evaluation of stability samples of batch 4/F191 
Test Specification Initial 1 mo 2 mo 3 mo 
Description White to off-white colored capsules. complies complies complies complies 
Average weight 222 mg±5% complies complies complies complies 
Assay 90-110% 99.8±0.7 100.3±1.7 99.3±1.1 99.1±2.0 
Drug release 3 h: 45±10% 43±0.9 43.9±2.7 46.4±3.5 42.6±3.2 
5 h: NLT 70% 74±2.7 73.9±2.7 76.4±3.5 72.6±3.2 
7 h: NLT 80% 83±1.8 93.2±1.4 95.2±2.5 91.5±1.9 
Values of assay and drug release are represented as mean±standard deviation, n=3, n=6 respectively 
 
CONCLUSION 
ER pellets prepared using mannitol as an osmotic agent/osmogent 
have shown the in vitro release of the drug similar to Detrol LA and 
subsequently exhibited complete release (more than 85%) at 12 h. 
This osmotic ER controlled formulation of tolterodine when 
administered once a day can thus be expected to achieve similar 
therapeutic effect as that of Detrol LA. 
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